Drug intelligence / Profile preview

APH-1504

Development stage: Preclinical
Lead developer: Aphios
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Oral

Overview

APH-1504 is an oral, extended-release nanoformulation of cannabidiol (CBD) being developed by Aphios Corporation for the treatment of multiple sclerosis (MS). Utilizing the proprietary SFS-PNS™ nanotechnology platform, the drug encapsulates CBD within biodegradable polymer nanoparticles to enhance bioavailability, improve central nervous system (CNS) penetration, and provide sustained release. APH-1504 targets the cannabinoid receptors CB1 and CB2 within the endocannabinoid system to address MS-related symptoms such as pain, inflammation, and spasticity, with the potential for disease-modifying effects.

Other names: APH-1504 CBD nanoformulationAPH1504 CBD nanoformulationAPH 1504 CBD nanoformulation

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on APH-1504.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APH-1504.

Explore the full profile